Patents by Inventor David Chatenet

David Chatenet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of prototypic galectin dimerization and uses thereof
    Patent number: 11319374
    Abstract: Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for, the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: May 3, 2022
    Assignee: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David Chatenet, Nicolas Doucet, Yves St-Pierre, Maria-Claudia Vladoiu
  • GALECTIN-7-SPECIFIC MONOVALENT ANTIBODIES AND USES THEREOF
    Publication number: 20220089746
    Abstract: Monovalent antibodies such as nanobodies that are specific for galectin-7 are described. These monovalent antibodies are able to interfere with the dimerization of galectin-7, and thus may be used for the treatment of diseases associated with dysregulated galectin-7 expression and/or activity, such as certain types of cancers as well as eye diseases or conditions associated with pathological neovascularization or angiogenesis.
    Type: Application
    Filed: January 9, 2020
    Publication date: March 24, 2022
    Inventors: David Chatenet, Nicolas Doucet, Yves St-Pierre
  • INHIBITORS OF PROTOTYPIC GALECTIN DIMERIZATION AND USES THEREOF
    Publication number: 20200071407
    Abstract: Agents that inhibit the dimerizaton of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7, The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dirnerization, for example for, the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.
    Type: Application
    Filed: November 15, 2019
    Publication date: March 5, 2020
    Inventors: David Chatenet, Nicolas Doucet, Yves St-Pierre, Maria-Claudia Vladoiu
  • Inhibitors of prototypic galectin dimerization and uses thereof
    Patent number: 10519239
    Abstract: Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: December 31, 2019
    Assignee: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David Chatenet, Nicolas Doucet, Yves St-Pierre, Maria-Claudia Vladoiu
  • INHIBITORS OF PROTOTYPIC GALECTIN DIMERIZATION AND USES THEREOF
    Publication number: 20180155432
    Abstract: Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.
    Type: Application
    Filed: May 25, 2016
    Publication date: June 7, 2018
    Inventors: David Chatenet, Nicolas Doucet, Yves St-Pierre, Maria-Claudia Vladoiu
  • Agonists and antagonists of the urotensinergic system
    Patent number: 9340575
    Abstract: Novel urotensin II receptor (UT) agonists and antagonists are described herein. More specifically, novel derivatives of urotensin II-related peptide (URP) are described herein.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: May 17, 2016
    Assignee: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David Chatenet, Alain Fournier, Myriam Letourneau
  • NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM
    Publication number: 20140113872
    Abstract: Novel urotensin ll receptor (UT) agonists and antagonists are described herein. More specifically, novel derivatives of urotensin ll-related peptide (URP) are described herein.
    Type: Application
    Filed: May 3, 2012
    Publication date: April 24, 2014
    Applicant: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David Chatenet, Alain Fournier, Myriam Letourneau
  • NPY ANTAGONISTS
    Publication number: 20120259092
    Abstract: Peptidic NPY antagonists selective for Y1 having an organic chelator, such as DOTA, coupled thereto which are useful for diagnostic procedures and receptor-mediated radiotherapy.
    Type: Application
    Filed: April 11, 2012
    Publication date: October 11, 2012
    Inventors: David Chatenet, Jean Claude Reubi, Jean E. F. Rivier